Akouos upsizes IPO by 50% as expected pricing increases - MarketWatch

Akouos upsizes IPO by 50% as expected pricing increases - MarketWatch

Biotech IPOs are looking good

Pandemic-driven market flux be damned. Biotech IPOs are doing mighty fine, turns out — Renaissance Capital reports that they have averaged an 80% return from their offer price on the year. About two dozen drug developers have gone public this year, and each has either priced above its midpoint, or upsized its share offering. 

The trend continued this week. Fusion Pharmaceuticals, which is developing next-gen radiation therapy for cancers, upped the size of its offering by 50% this week. Gene therapy player Akouos did the same.